Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiloride + enalapril is a combination of two antihypertensive agents used together to manage high blood pressure (hypertension) and, in some cases, heart failure. Amiloride is a potassium-sparing diuretic that acts on the distal renal tubules to inhibit sodium reabsorption while reducing potassium excretion. Enalapril is an angiotensin-converting enzyme (ACE) inhibitor prodrug that blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone-mediated sodium retention. The combination may be considered in patients who require both mechanisms for optimal blood pressure control but must be used with caution due to the risk of hyperkalemia from additive effects on potassium retention[3][4][6]. This combination does not have a widely recognized fixed-dose brand formulation but may be prescribed as separate agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amiloride + enalapril.